EX-4.2



 EXHIBIT 4.2 

THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

BY AND AMONG 
 ZAFGEN,
INC. 
 AND 
 THE
INVESTORS NAMED HEREIN 
 November 25, 2013 







 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	Section 1.	 	 Definitions
	  	 	1	  
			
	Section 2.	 	 Registration Rights
	  	 	5	  
	 2.1
	 	 Demand Registration
	  	 	5	  
	 2.2
	 	 Company Registration
	  	 	6	  
	 2.3
	 	 Form S-3 Registration
	  	 	6	  
	 2.4
	 	 Underwriting Requirements
	  	 	7	  
	 2.5
	 	 Obligations of the Company
	  	 	8	  
	 2.6
	 	 Furnish Information
	  	 	9	  
	 2.7
	 	 Expenses of Registration
	  	 	10	  
	 2.8
	 	 Delay of Registration
	  	 	10	  
	 2.9
	 	 Indemnification
	  	 	10	  
	 2.10
	 	 Reports Under Exchange Act
	  	 	12	  
	 2.11
	 	 Limitations on Subsequent Registration Rights
	  	 	13	  
	 2.12
	 	 “Market Stand-off” Agreement
	  	 	13	  
	 2.13
	 	 Assignment of Registration Rights
	  	 	14	  
	 2.14
	 	 Restrictions on Transfer
	  	 	14	  
	 2.15
	 	 Termination of Registration Rights
	  	 	16	  
			
	Section 3.	 	 Information and Observer Rights
	  	 	16	  
	 3.1
	 	 Delivery of Financial Statements
	  	 	16	  
	 3.2
	 	 Inspection
	  	 	17	  
	 3.3
	 	 Observer Rights
	  	 	18	  
	 3.4
	 	 Termination of Information and Observer Rights
	  	 	18	  
	 3.5
	 	 Confidentiality
	  	 	18	  
			
	Section 4.	 	 Rights to Future Stock Issuances
	  	 	19	  
	 4.1
	 	 Right of First Offer
	  	 	19	  
	 4.2
	 	 Termination
	  	 	20	  
			
	Section 5.	 	 Additional Covenants
	  	 	20	  
	 5.1
	 	 Insurance
	  	 	20	  
	 5.2
	 	 Employee Agreements
	  	 	20	  
	 5.3
	 	 Employee Vesting
	  	 	21	  
	 5.4
	 	 Matters Requiring Holder Approval
	  	 	21	  
	 5.5
	 	 Meetings of the Board of Directors
	  	 	22	  
	 5.6
	 	 Successor Indemnification
	  	 	22	  
	 5.7
	 	 Sudanese Investments
	  	 	22	  
	 5.8
	 	 Termination of Covenants
	  	 	23	  
			
	Section 6.	 	 Miscellaneous
	  	 	23	  
	 6.1
	 	 Successors and Assigns
	  	 	23	  
	 6.2
	 	 Governing Law
	  	 	23	  









							
	 6.3
	 	 Counterparts
	  	 	23	  
	 6.4
	 	 Titles and Subtitles
	  	 	23	  
	 6.5
	 	 Notices
	  	 	23	  
	 6.6
	 	 Amendments and Waivers
	  	 	24	  
	 6.7
	 	 Severability
	  	 	25	  
	 6.8
	 	 Aggregation of Stock
	  	 	25	  
	 6.9
	 	 Additional Investors
	  	 	25	  
	 6.10
	 	 Termination of Prior Agreement; Entire Agreement
	  	 	25	  
	 6.11
	 	 Dispute Resolution
	  	 	25	  
	 6.12
	 	 Delays or Omissions
	  	 	26	  

 SCHEDULE A – Schedule of Investors 

  
 ii 








 THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of November 25,
2013, by and between Zafgen, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any
additional Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof. 
 RECITALS 

WHEREAS, the Company and the holders of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D
Preferred Stock previously entered into that certain Second Amended and Restated Investors’ Rights Agreement, dated June 30, 2011, as amended by that certain Amendment No. 1 to the Second Amended and Restated Investors’ Rights
Agreement, dated November 30, 2012 (the “Prior Agreement”), which Prior Agreement includes certain registration rights, information rights and purchase rights, among other rights; 

WHEREAS, the Company and certain of the Investors are parties to that certain Series E Preferred Stock Purchase Agreement of even date
herewith (as amended, restated and otherwise modified from time to time, the “Purchase Agreement”); and 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce those certain Investors who are party to the
Purchase Agreement to invest funds in the Company pursuant to the Purchase Agreement, the parties to the Prior Agreement desire to terminate the Prior Agreement in its entirety and to replace and supersede the Prior Agreement with this Agreement,
which shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and
shall govern certain other matters as set forth in this Agreement. 
 NOW, THEREFORE, the parties hereby agree as follows: 

Section 1. Definitions. 

For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who or which, directly or indirectly, controls,
is controlled by, or is under common control with such specified Person, including without limitation any partner, officer, director, manager or employee of such Person and any venture capital fund now or hereafter existing that is controlled by or
under common control with one or more general partners or managing members of, or snares the same management company with, such Person. 

1.2 “Atlas Venture” means Atlas Venture Fund VII, L.P. 

1.3 “Board of Directors” means the Company’s Board of Directors. 







 1.4 “Certificate of Incorporation” means the Company’s Seventh Amended and
Restated Certificate of Incorporation, as the same may be amended, restated or otherwise modified from time to time. 
 1.5 “Common
Stock” means shares of the Company’s common stock, par value $0.001 per share. 
 1.6 “Damages” means any
loss, claim, damage, or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, claim, damage, or liability (or any action in respect
thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged
violation by any other party hereto of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.7 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for, Common Stock,
including options and warrants. 
 1.8 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder. 
 1.9 “Excluded Registration” means a registration relating either to the sale of
securities to employees of the Company pursuant to a stock option, stock purchase, or similar plan or to an SEC Rule 145 transaction; a registration on any form that does not include substantially the same information as would be required to be
included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

1.10 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form
under the Securities Act subsequently adopted by the SEC. 
 1.11 “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 
 1.12
“GAAP” means generally accepted accounting principles in the United States. 
 1.13 “Holder” means any
holder of Registrable Securities who is a party to this Agreement. 

  
 2 








 1.14 “Immediate Family Member” means a child, stepchild, grandchild, parent,
stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein. 

1.15 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement. 

1.16 “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act. 

1.17 “Key Employee” means any executive-level employee (including division director and vice president-level positions) as
well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement). 

1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as
rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.19 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 1.20 “Preferred Directors” means the Series A Directors and Series B/C Directors. 

1.21 “Preferred Stock” means, collectively, shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred
Stock, Series D Preferred Stock and Series E Preferred Stock. 
 1.22 “Qualified Offering” means an underwritten public
offering of Common Stock pursuant to an effective registration statement under the Securities Act resulting in at least $35,000,000 of proceeds, net of the underwriting discount and commissions, to the Company. 

1.23 “Register,” “registered,” and “registration” refer to a registration effected by
preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

1.24 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock;
(ii) any Common Stock issued or issuable upon conversion of any capital stock of the Company acquired by the Investors after the date hereof; (iii) any Common Stock issued to or acquired by the Investors after the date hereof; and
(iv) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares
referenced in clauses (i), (ii) and (iii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the rights under Section 2 hereof are not assigned or any shares for which
registration rights have terminated pursuant to Section 2.15 of this Agreement. 

  
 3 








 1.25 “Registrable Securities then outstanding” means the number of shares
determined by adding the Common Stock outstanding and the Common Stock issuable pursuant to then exercisable or convertible securities, in each case, that are Registrable Securities. 

1.26 “Restricted Securities” means the securities of the Company required to bear the legend set forth in
Section 2.14(b) hereof. 
 1.27 “SEC” means the Securities and Exchange Commission. 

1.28 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.29 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.30 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

1.31 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale
of Registrable Securities, and fees and disbursements of counsel for any Holder, except as provided in Section 2.7. 
 1.32
“Series A Directors” means the directors of the Company that the holders of record of the Series A Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation. 

1.33 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, par value $0.001 per share. 

1.34 “Series B/C Directors” means the directors of the Company that the holders of record of the Series B Preferred Stock and
Series C Preferred Stock are entitled to elect pursuant to the Certificate of Incorporation. 
 1.35 “Series B Preferred
Stock” means shares of the Company’s Series B Preferred Stock, par value $0.001 per share. 
 1.36 “Series C Preferred
Stock” means shares of the Company’s Series C Preferred Stock, par value $0.001 per share. 
 1.37 “Series D Preferred
Stock” means shares of the Company’s Series D Preferred Stock, par value $0.001 per share. 
 1.38 “Series E Preferred
Stock” means shares of the Company’s Series E Preferred Stock, par value $0.001 per share. 

  
 4 








 Section 2. Registration Rights. 

The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty
(180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least seventy percent (70%) of the Registrable Securities then outstanding that the Company effect a
registration with respect to Registrable Securities then outstanding (voting together as a single class), then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the “Demand
Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file, a registration statement
under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(b). 

(b) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration
statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate
reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company
unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing for a period of not more than thirty (30) days after the request of the
Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own
account or that of any other stockholder during such thirty (30) day period other than pursuant to a registration relating to the sale of securities to employees of the Company pursuant to a stock option, stock purchase, or similar plan or a
registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

(c) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this Section 2.1
(i) during the period that is ninety (90) days after the effective date of a Company-initiated registration on Form S-l, (ii) after the Company has effected two demand registrations pursuant to this Section 2.1; or
(iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately 

  
 5 








 
registered on Form S-3 pursuant to a request made pursuant to Section 2.3. A registration shall not be counted as “effected” for purposes of this Section 2.1
until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right
to one demand registration statement pursuant to Section 2.1, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1. 

2.2 Company Registration. 

If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the
Holders) any of its stock or other securities under the Securities Act in connection with the public offering of such securities solely for cash (other than an Excluded Registration), the Company shall, at such time, promptly give each Holder notice
of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.4, cause to be registered all of the
Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date
of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses of such withdrawn registration shall be borne by the Company in accordance with Section 2.1. 

2.3 Form S-3 Registration. 

If the Company receives a request from Holders of at least ten percent (10%) of the Registrable Securities then outstanding that the
Company effect a registration on Form S-3 with respect to all or a part of the Registrable Securities owned by such Initiating Holders, then the Company shall: 

(a) within ten (10) days after the date such request is given, give notice of the proposed registration to all Holders other than the
Initiating Holders (the “S-3 Notice”); and 
 (b) as soon as practicable, use its commercially reasonable efforts to effect
such registration as would permit or facilitate the sale and distribution of all or such portion of such Initiating Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable
Securities of any other Holders joining in such request as are specified in a request given to the Company within fifteen (15) days after the S-3 Notice is given; provided, however, that the Company shall not be obligated to
effect any such registration pursuant to this Section 2.3 (i) if Form S-3 is not then available for such offering by the Holders; (ii) if the Holders, together with the holders of any other securities of the Company entitled to
and requesting inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than $500,000.00; (iii) if the Company furnishes to the Holders a certificate
signed by the chief executive officer of the Company stating that in the good-faith judgment of the Board of Directors, it would be materially detrimental to the Company and its stockholders for such Form


  
 6 








 
S-3 registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a period of not more than thirty
(30) days after receipt of the request of the Initiating Holders under this Section 2.3; provided, however, that the Company shall not invoke this right more than once in any twelve (12) month period; and
provided further that the Company shall not register any securities for its own account or that of any other stockholder during such thirty (30) day period other than pursuant to a registration relating to the sale of securities to
employees of the Company pursuant to a stock option, stock purchase, or similar plan or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 

(c) Registrations effected pursuant to this Section 2.3 shall not be counted as demands for registration or registrations effected
pursuant to Section 2.1. 
 2.4 Underwriting Requirements. 

(a) If, pursuant to Section 2.1 or Section 2.3, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1(a) or Section 2.3, and the Company shall include such information in the Demand
Notice or the S-3 Notice, as the case may be. The underwriter will be selected by the Initiating Holders, subject only to the reasonable approval of the Company. In such event, the right of any Holder to include such Holder’s Registrable
Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing
to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.5(e)) enter into an underwriting agreement in customary form with the managing underwriters) selected for such
underwriting. Notwithstanding any other provision of this Section 2.4, if the managing underwriters advise the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the
Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among all Holders of
Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder; provided, however, that the number of Registrable Securities held by the
Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the Company or the
underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 
 (b) In connection with any offering
involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept
the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total
number of securities, including Registrable Securities, requested by stockholders to be included in such offering 

  
 7 








 
exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the
Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. In
no event shall any Registrable Securities be excluded from such offering unless all other stockholders’ securities have been first excluded. If the underwriters determine that less than all of the Registrable Securities requested to be
registered can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in
such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total
number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are
included in such offering. For purposes of the provision in this Section 2.4(b) concerning apportionment, for any selling stockholder that is a Holder and a partnership, limited liability company, or corporation, the partners, members,
retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing
Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons
included in such “selling Holder,” as defined in this sentence. 
 2.5 Obligations of the Company. 

Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible: 
 (a) prepare and file with the SEC a registration statement with respect to such Registrable
Securities and use its commercially reasonable efforts to cause such registration statement to become effective and keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the
distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains,
at the request of an underwriter of Common Stock (or other securities), from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on
a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to sixty (60) days, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and
the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

  
 8 








 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a
preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available for
inspection by the selling Holders, any underwriter participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all
financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller,
underwriter, attorney, accountant, or agent in connection with any such registration statement; 
 (i) notify each selling Holder, promptly
after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 2.6 Furnish Information. 

It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to
the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably
required to effect the registration of such Holder’s Registrable Securities. 

  
 9 








 2.7 Expenses of Registration. 

All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to
Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling
Holders, shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 or Section 2.3 if
the registration request is subsequently withdrawn at the request of the Holders of at least seventy percent (70%) of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon
the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of at least seventy percent (70%) of the Registrable Securities agree to forfeit their right to one registration pursuant to
Section 2.1 or Section 2.3, as the case may be; provided further that if, at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company
from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall not forfeit their
right to one registration pursuant to Section 2.1 or Section 2.3. All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on
the basis of the number of Registrable Securities registered on their behalf. 
 2.8 Delay of Registration. 

No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as
the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 2.9
Indemnification. 
 If any Registrable Securities are included in a registration statement under this Section 2: 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the
meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in
connection with investigating any matter or defending any proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.9(a) shall not
apply to amounts paid in settlement of any such investigation or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the
extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person
expressly for use in connection with such registration. 

  
 10 








 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating any investigation or defending any proceeding from which
Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.9(b) shall not apply to amounts paid in settlement of any such investigation or proceeding if
such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall any indemnity under this Section 2.9(b) exceed the proceeds from the
offering (net of any Selling Expenses) received by such Holder, except in the case of fraud or willful misconduct by such Holder. 
 (c)
Promptly after receipt by an indemnified party under this Section 2.9 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party
will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.9. give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such
action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided,
however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the
indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by
such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this
Section 2.9, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to
any indemnified party otherwise than under this Section 2.9. 
 (d) To provide for just and equitable contribution to joint
liability under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.9 but it is judicially determined (by the
entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such 

  
 11 








 
indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.9 provides for indemnification in such case, or (ii) contribution under the
Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.9, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities,
or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of the each of indemnifying party and the indemnified party in connection with the statements, omissions, or
other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by
reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and
the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any
amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this
Section 2.9(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.9(b), exceed the proceeds from the offering (net of any Selling Expenses) received by such Holder, except in the case of
willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Section 2.9 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 2.10 Reports Under Exchange Act. 

With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time
permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep public information available, as those terms are understood and defined in SEC Rule 144, at all times after the effective
date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file with the SEC in a
timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

  
 12 








 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon
request (i) a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the
IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company
so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has
become subject to the reporting requirements under the Exchange Act) or pursuant to such Form S-3 (at any time after the Company so qualifies to use such form). 

2.11 Limitations on Subsequent Registration Rights. 

From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least seventy percent
(70%) of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (i) to include such securities in any
registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable
Securities of the Holders that are included or (ii) to demand registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any Additional Investor who becomes a party to this
Agreement in accordance with Section 6.9. 
 2.12 “Market Stand-off” Agreement. 

Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the
date of the final prospectus relating to the IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may be requested by the Company or
an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule
2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right,
or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the
effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such
transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.12 shall apply only to the IPO, shall


  
 13 








 
not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers, directors and stockholders individually
owning more than one percent (1%) of the outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such
registration are intended third party beneficiaries of this Subsection 2.12 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as
may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.12 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of
any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

2.13 Assignment of Registration Rights. 

The rights to cause the Company to register Registrable Securities pursuant to this Section 2 may be assigned (but only with all
related obligations) by a Holder to a transferee of such Registrable Securities that (i) is an Affiliate, partner, member, limited partner, retired partner, retired member, or stockholder of a Holder; (ii) is a Holder’s Immediate
Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least 100,000 shares of Registrable Securities (subject to appropriate
adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (y) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and
address of such transferee and the Registrable Securities with respect to which such registration rights are being transferred and (z) such transferee agrees in writing to be bound by and subject to the terms and conditions of this Agreement,
including the provisions of Section 2.12. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (i) that is an Affiliate, limited partner, retired partner,
member, retired member, or stockholder of a Holder; (ii) who is a Holder’s Immediate Family Member; or (iii) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated
together and with those of the transferring Holder; provided further that all transferees other than limited partners, retired partners and stockholders of a Holder who would not qualify individually for assignment of registration rights
shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Section 2. 

2.14 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed
purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

  
 14 








 (b) Each certificate representing (i) the Preferred Stock, (ii) the Registrable
Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise
permitted by the provisions of Section 2.14(c)) be stamped or otherwise imprinted with a legend in the following form: 
 THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID
EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE
TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities
in order to implement the restrictions on transfer set forth in this Section 2.14. 
 (c) The holder of each certificate
representing Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a
registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the
manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall,
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter
from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other
evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted
Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter
(x) in any transaction in compliance with Rule 144 or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing
to be subject to the terms of this Section 2.14(c). Each certificate evidencing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legend
set forth in Section 2.14(b), except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any
provisions of the Securities Act. 

  
 15 








 2.15 Termination of Registration Rights. 

The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1,
Section 2.2 or Section 2.3 shall terminate upon the earlier of: 
 (a) the closing of a Deemed Liquidation Event, as
such term is defined in the Certificate of Incorporation; or 
 (b) when all of such Holder’s Registrable Securities could be sold
without restriction under SEC Rule 144. 
 Section 3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. 

For so long as any shares of Preferred Stock are outstanding, the Company shall deliver to each Investor: 

(a) as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company, (i) a balance
sheet as of the end of such year; (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as
included in the Budget (as defined in Section 3.1(e)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year; and (iii) a
statement of stockholders’ equity as of the end of such year, audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, unaudited statements of income and of cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance
with GAAP (except that the financial report may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of
each fiscal year of the Company, a statement showing the number of shares of each class and scries of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock
issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet
issued but reserved for issuance, if any, all in sufficient detail as to permit the Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the
Company as being true, complete, and correct; 

  
 16 








 (d) as soon as practicable, but in any event within thirty (30) days of the end of each
month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with GAAP (except that the financial
report may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(e) as soon as practicable, but in any event sixty (60) days before the end of each fiscal year, a budget and business plan for the next
fiscal year (collectively, the “Budget”), prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets
prepared by the Company; 
 (f) with respect to the financial statements called for in Section 3.1(a),
Section 3.1(b) and Section 3.1(d), an instrument executed by the chief financial officer and chief executive officer of the Company certifying that such financial statements were prepared in accordance with GAAP consistently
applied with prior practice for earlier periods (except as otherwise set forth in Section 3.1(b) and Section 3.1(d)) and fairly present the financial condition of the Company and its results of operation for the periods
specified therein; and 
 (g) such other information relating to the financial condition, business, prospects, or corporate affairs of the
Company as any Investor, including any such Investor’s affiliates and limited partners, may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to
provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or (ii) the
disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the
Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial
statements of the Company and all such consolidated subsidiaries. 
 Notwithstanding anything else in this Section 3.1 to the
contrary, the Company may cease providing the information set forth in this Section 3.1 upon the completion of a Qualified Offering. 

3.2 Inspection. 

The Company shall permit each Investor, including any such Investor’s Affiliates and limited partners, at such Investor’s
expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably
requested by the Investor, provided, however, that the Company shall not be obligated pursuant  

  
 17 








 
to this Section 3.2 to provide access to any information that it reasonably considers to be a trade secret or confidential information (unless covered by an enforceable
confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Observer Rights. 
 As
long as (i) Atlas Venture holds any shares of Preferred Stock or Common Stock, the Company shall invite a representative of Atlas Venture to attend all meetings of its Board of Directors and all meetings of committees of the Board of Directors
in a nonvoting observer capacity, (ii) Third Rock Ventures, LP (“Third Rock”) holds any shares of Preferred Stock or Common Stock, the Company shall invite a representative of Third Rock to attend all meetings of its Board of
Directors and all meetings of committees of the Board of Directors in a nonvoting observer capacity, (iii) Alta Partners VIII, LP (“Alta Partners”) or any Affiliate of Alta Partners holds any shares of Preferred Stock or Common
Stock, the Company shall invite a representative of Alta Partners to attend all meetings of its Board of Directors and all meetings of committees of the Board of Directors in a nonvoting observer capacity and (iv) RA Capital Management, LLC
(“RA Capital”) or any Affiliate of RA Capital holds any shares of Preferred Stock or Common Stock, the Company shall invite a representative of RA Capital to attend all meetings of its Board of Directors in a nonvoting observer
capacity, and, in this respect, shall give any such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the same time and in the same manner as provided to such directors;
provided, however, that any such representative shall agree to hold in confidence and trust and to act in a fiduciary manner with respect to all information so provided; and provided further, that the Company reserves the right
to withhold any information and to exclude any such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its
counsel or result in disclosure of trade secrets or a conflict of interest, or if such Investor or its representative is a competitor of the Company. To the extent the Company provides indemnification to any Board of Directors observer, it shall
provide the same indemnification to all such observers. The Company will reimburse the representative of Alta Partners pursuant to this section for the reasonable expenses incurred by such representative for travel to attend meetings of the Board of
Directors or any committee of the Board of Directors. 
 3.4 Termination of Information and Observer Rights. 

The covenants set forth in Sections 3.1, 3.2 and 3.3 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO or (ii) upon a Deemed Liquidation Event, whichever event occurs first. 
 3.5
Confidentiality. 
 Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a 

  
 18 








 
result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential
information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may
disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective
purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of
such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise
be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. The Company acknowledges that certain of the Investors are in
the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises that may have products or services that compete directly or indirectly with those of the
Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise, regardless of whether such enterprise has products or services that compete with those of the
Company. 
 Section 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. 

Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes to offer or sell
any New Securities, the Company shall first offer such New Securities to each Investor. An Investor shall be entitled to apportion the right of first offer hereby granted to it among itself and its Affiliates in such proportions as it deems
appropriate. 
 (a) The Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide
intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Investor may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock issued and held, or issuable upon conversion of the Preferred Stock and any
other Derivative Securities then held, by such Investor bears to the total Common Stock then outstanding (assuming full conversion and exercise of all Preferred Stock and all other Derivative Securities). At the expiration of such twenty
(20) day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise.
During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to
that portion of the New 

  
 19 








 
Securities for which Investors were entitled to subscribe but that were not subscribed for by the Investors which is equal to the proportion that the Common Stock issued and held, or issuable
upon conversion of Preferred Stock then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all Fully Exercising Investors who wish to purchase such
unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within sixty (60) days of the date that the Offer Notice is given. 

(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in
Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any
Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such
agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with
this Section 4.1. 
 (d) The right of first offer in this Section 4.1 shall not be applicable to Exempted Securities (as
defined in the Certificate of Incorporation). 
 4.2 Termination. 

The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the
consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 13(a) or 15(d) of the Exchange Act or (iii) upon a Deemed Liquidation Event, whichever event occurs first. 

Section 5. Additional Covenants. 

5.1 Insurance. 
 The
Company shall use its commercially reasonable efforts to maintain from financially sound and reputable insurers Directors and Officers Errors and Omissions insurance in an amount satisfactory to the Board of Directors, including the Preferred
Directors. Such policy shall not be cancelable by the Company without prior approval of the Board of Directors, including the Preferred Directors. 

5.2 Employee Agreements. 

The Company will cause (i) each Person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary
as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement and (ii) each Key Employee to enter into a one (1) year
noncompetition and nonsolicitation agreement, substantially in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced
agreements or any restricted stock agreement between the Company and any employee, without the consent of the Preferred Directors. 

  
 20 








 5.3 Employee Vesting. 

Unless otherwise approved by the Board of Directors, including the Preferred Directors, all future employees and consultants of the Company who
purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares
over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the
following thirty-six (36) months, and (ii) a one hundred eighty (180) day lockup period in connection with the IPO. The Company shall retain a “right of first refusal” on employee transfers until the IPO and shall have the
right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock. 
 5.4 Matters Requiring
Holder Approval. 
 So long as any shares of Preferred Stock are outstanding, the Company hereby covenants and agrees with each of the
Investors that it shall not, without the approval of the Board of Directors, including the approval of the Preferred Directors: 
 (a) make,
or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the
Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c) grant a security interest in the assets of the Company other than in the ordinary course of business; 

(d) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (e) make any payment or investment or incur any
aggregate indebtedness in excess of $50,000.00 that is not already included the Budget, other than trade credit incurred in the ordinary course of business; 

(f) enter into or be a party to any transaction with any director, officer or employee of the Company or any “associate” (as defined
in Rule 12b-2 promulgated under the Exchange Act) of such Person, except for transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business upon fair and reasonable terms that are approved
by a majority of the members of the Board of Directors; 

  
 21 








 (g) hire, terminate, or change the compensation of any officer or senior executive of the
Company, including approving any option grants or stock awards to such officer or senior executive; 
 (h) change the principal business of
the Company or any subsidiary, enter into a new line of business or exit the current line of business; 
 (i) approve, or amend in any
material respect, the Budget; 
 (j) in any fiscal year, incur capital or other expenditures materially in excess of the amounts
contemplated by the approved Budget for that fiscal year (or, until such time as a Budget is approved for any fiscal year, the amounts contemplated by the approved Budget for the preceding fiscal year); 

(k) commence or settle any litigation where the litigation relates to the business of the Company generally and the amount involved exceeds
$10,000 in the aggregate; 
 (l) confess a judgment against the Company in an amount exceeding $10,000; 

(m) enter into any agreement, arrangement or transaction that is material to the Company; or 

(n) adopt any new or amend any existing stock plan, employee stock ownership plan or phantom stock or similar plan to increase the aggregate
number of shares reserved under such plans to more than 11,863,864 in the aggregate. 
 5.5 Meetings of the Board of Directors. 

Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in
accordance with an agreed-upon schedule. 
 5.6 Successor Indemnification. 

If the Company or any of its successors or assignees (i) consolidates with or merges into any other Person and is not the continuing or
surviving corporation or entity of such consolidation or merger or (ii) transfers or conveys all or substantially all of its properties and assets to any Person, then, and in each such case, to the extent necessary, proper provision shall be
made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are
contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 5.7 Sudanese
Investments. 
 The Company and each of its subsidiaries shall not, directly or indirectly, own or control any property or assets located
in the Republic of Sudan or transact any commercial business in the Republic of Sudan. 

  
 22 








 5.8 Termination of Covenants. 

The covenants set forth in this Section 5, except for Section 5.6, shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 13(a) or 15(d) of the Exchange Act or (iii) upon a Deemed Liquidation Event,
whichever event occurs first. 
 Section 6. Miscellaneous. 

6.1 Successors and Assigns. 

Each Investor hereby agrees that it shall not, and may not, assign any of its rights and obligations hereunder, unless such rights and
obligations are assigned by such Investor to any Person to which Registrable Securities are transferred by such Investor pursuant to Section 2.13, and such assignee shall be deemed an “Investor” for purposes of this Agreement;
provided that such assignment of rights shall be contingent upon the assignee providing a written instrument to the Company notifying the Company of such assignment and agreeing in writing to be bound by the terms of this Agreement. The terms
and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. 
 This
Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to its principles of conflicts of laws. 

6.3 Counterparts. 
 This
Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed and delivered by facsimile signature or
other form of electronic transmission (including pdf) and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

6.4 Titles and Subtitles. 

The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this
Agreement. 
 6.5 Notices. 

All notices, requests, and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day;
(iii) five (5) days after having been sent by registered or certified mail, return receipt requested, 

  
 23 








 
postage prepaid; or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next-day delivery, with written verification of receipt. All communications
shall be sent to the respective parties at their addresses as set forth on the signature page or Schedule A hereto, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with
this Section 6.5. If notice is given to the Company, a copy (which shall not constitute notice) shall also be sent to Goodwin Procter LLP, Exchange Place, Boston, MA 02109, fax: (617) 523-1231, Attention: Mitchell S. Bloom,
Esq., email: mbloom@goodwinprocter.com. 
 6.6 Amendments and Waivers. 

Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular
instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least seventy percent (70%) of the Registrable Securities then outstanding; provided that the Company may in its sole
discretion waive compliance with Section 2.14(c) (and the Company’s failure to object promptly in writing to a proposed assignment (after notice thereof to the Company in accordance with Section 6.5) allegedly in
violation of Section 2.14(c) shall be deemed to be a waiver). Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the
written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be
deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction); provided that
Section 3.3 and this sentence of Section 6.6 of this Agreement may not be amended or terminated and the observance of any term of Section 3 may not be waived with respect to Atlas, Third Rock, Alta Partners or RA
Capital without the written consent of Atlas, Third Rock, Alta Partners or RA Capital, respectively; and provided further, that notwithstanding the foregoing, the terms and conditions of this Agreement as they apply to Fidelity Select Portfolios:
Biotechnology Portfolio (“Fidelity Select”), Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund (“Fidelity Advisor” and together with Fidelity Select, the “Fidelity Investors”) or
their Affiliates or related parties may not be modified or amended without the prior written consent of the Fidelity Investors, as applicable; and provided further, that notwithstanding the foregoing, the terms and conditions of this Agreement as
they apply to RA Capital or its Affiliates or related parties may not be modified or amended without the prior written consent of RA Capital. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any
party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any
such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or
provision. Notwithstanding the foregoing, Schedule A may be amended from time to time by the Company without the consent of the holders of at least seventy percent (70%) of the Registrable Securities then outstanding to reflect a
transfer of Registrable Securities permitted by Section 2.14(c) or the issuance of new Registrable Securities in accordance with Section 4.1 or pursuant to Section 6.9. 

  
 24 








 6.7 Severability. 

In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable
to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. 

All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the
availability of any rights under this Agreement. 
 6.9 Additional Investors. 

Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the Preferred Stock after the date
hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all
purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all of the obligations as an
“Investor” hereunder. 
 6.10 Termination of Prior Agreement; Entire Agreement. 

The Company and the holders of at least seventy percent (70%) of the Registrable Securities (as defined in the Prior Agreement) then
outstanding hereby agree that, as of the date of this Agreement, (x) the Prior Agreement is hereby superseded in its entirety by this Agreement, and (y) the original terms of the Prior Agreement shall not have any further force or effect.
This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties is expressly canceled. 
 6.11 Dispute Resolution. 

The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Massachusetts and to the
jurisdiction of the U.S. District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding
arising out of or based upon this Agreement except in the state courts of Massachusetts or the U.S. District Court for the District of Massachusetts, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise,
in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in
an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. Each of the parties to this Agreement consents to personal jurisdiction
for any equitable action sought in the U.S. District Court for the District of Massachusetts or any court of the Commonwealth of Massachusetts having subject matter jurisdiction. 

  
 25 








 6.12 Delays or Omissions. 

No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any
other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or
default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to
any party, shall be cumulative and not alternative. 
 [Remainder of Page Intentionally Left Blank] 

  
 26 








 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	ZAFGEN, INC.
		
	By:	 	/s/ Thomas Hughes
	Name:	 	Thomas Hughes
	Title:	 	President and CEO
		
	Address:	 	One Broadway, 8th Floor
		 	Cambridge, MA 02142


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	RA CAPITAL MANAGEMENT, LLC
		
	By:	 	/s/ Peter Kolchinsky
	Name:	 	Peter Kolchinsky
	Title:	 	Manager


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	ATLAS VENTURE FUND VII, L.P.
		
	        By:	 	Atlas Venture Associates VII, L.P.
	               Its General Partner
		
	        By:	 	Atlas Venture Associates VII, Inc.
	
	               Its General Partner


 
			
		
	By:	 	/s/ Kristen Laguerre
	Name:	 	Kristen Laguerre
	Title:	 	Vice President


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	THIRD ROCK VENTURES, LP
	
	By: Third Rock Ventures, GP, LP, its General Partner
	
	By: TRV GP, LLC, its General Partner
		
	By:	 	/s/ Kevin Gillis
	Name:	 	Kevin Gillis
	Title:	 	CFO


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	ALTA PARTNERS VIII, LP
	
	By: Alta Partners Management VIII, LLC, its General Partner
		
	By:	 	/s/ Larry Randall
	Name:	 	Larry Randall
	Title:	 	CFO


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	FIDELITY SELECT PORTFOLIOS: BIOTECHNOLOGY PORTFOLIO
		
	By:	 	/s/ Stacie M. Smith
	Name:	 	Stacie M. Smith
	Title:	 	Deputy Treasurer
	
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR BIOTECHNOLOGY FUND
		
	By:	 	/s/ Stacie M. Smith
	Name:	 	Stacie M. Smith
	Title:	 	Deputy Treasurer


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	BROOKSIDE CAPITAL PARTNERS FUND, L.P.
		
	By:	 	/s/ Adam M. Koppel
	Name:	 	Adam M. Koppel
	Title:	 	Managing Director


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	VENROCK HEALTHCARE CAPITAL PARNTERS, L.P.
	
	By: VHCP Management, LLC
	Its: General Partner
		
	By:	 	/s/ David L. Stepp
	Name:	 	David L. Stepp
	Title:	 	Authorized Signatory
	
	VHCP CO-INVESTMENT HOLDINGS, LLC
	
	By: VHCP Management, LLC
	Its: Manager
		
	By:	 	/s/ David L. Stepp
	Name:	 	David L. Stepp
	Title:	 	Authorized Signatory


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	AGMAN INVESTMENTS LLC
	
	By: Sion Management LLC
		
	By:	 	/s/ Howard Scott Silverman
	Name:	 	Howard Scott Silverman
	Title:	 	Manager


 [SIGNATURE PAGE TO INVESTORS’ RIGHTS AGREEMENT] 







 SCHEDULE A 

Investors 
 RA Capital Management, LLC 

20 Park Plaza, Suite 1200 
 Boston, MA 02116 

Atlas Venture Fund VII, L.P. 
 25 First Street, Suite 303 

Cambridge, MA 02141 
 Attn: General Counsel 

Third Rock Ventures, LP 
 29 Newbury St. 

Boston, MA 02116 
 Alta Partners VIII, LP 

One Embarcadero Center 
 37th Floor 
 San Francisco, CA 94111 

Fidelity Select Portfolios: Biotechnology Portfolio 
 Notice to:

 Brown Brothers Harriman & Co. 
 525 Washington Blvd

 Jersey City NJ 07310 
 Attn: Michael Lerman 15th Floor 

Corporate Actions 
 Email: michael.lerman@bbh.com 

Fax number: 617 772-2418 
 Fidelity Advisor Series VII: Fidelity
Advisor Biotechnology Fund 
 Notice to: 
 State Street
Bank & Trust 
 PO Box 5756 
 Boston, Massachusetts
02206 
 Attn: Bangle & Co fbo Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund 

Email: SSBCORPACTIONS@StateStreet.com 
 Fax number: 617-988-9110

 Brookside Capital Partners Fund, L.P. 
 Venrock Healthcare
Capital Partners, L.P. 
 VHCP Co-Investment Holdings, LLC 







 Matthias Jaffe 
 134
Highwoods Lane 
 Carlisle, MA 01741 
 Kimmel Family Trust 

543 Channing Avenue 
 Palo Alto, CA 94301 

Weiss Family Trust 
 100 Irvine Cove Place 

Laguna Beach, CA 92561 
 Megan Weiss 

1302 N. Sweetzer Avenue 
 West Hollywood, CA 90069 

  
 37